Community/Retail

FDA considers relaxing dietary supplement warning labels, raising concerns about consumer safety and informed decision-making among users.

A severe yet often overlooked coinfection with hepatitis B, hepatitis D progresses rapidly—but new therapies are beginning to reshape a long-limited treatment landscape.

GLP-1 receptor agonists show potential in reducing alcohol cravings and addiction behaviors, offering hope for treating substance use disorders.

Expert highlights the critical need to manage skin toxicities in oncology, ensuring effective cancer treatments while addressing patient well-being and adherence.

The FDA approval of Boncresa and Oziltus, new denosumab biosimilars, enhances access to treatments for osteoporosis and cancer-related bone loss.

Pharmacists optimize dopaminergic therapy, mitigate medication-induced psychosis, and guide antipsychotic selection to improve outcomes in Parkinson disease psychosis.

New research highlights the efficacy and safety of HRS-1780, an investigational nonsteroidal MRA, in treating chronic kidney disease (CKD).

New findings on nodal radiation for breast cancer patients highlight the importance of lymph node involvement and tumor size in treatment decisions.

A long-term study reveals that high-fat cheese consumption may lower dementia risk, challenging traditional views on dietary fat and brain health.

The FLEX study enhances breast cancer treatment by integrating genomic data, guiding therapy choices, and improving patient outcomes.

Research reveals that wildfire smoke exposure significantly impacts pediatric asthma control in the northeastern US, highlighting urgent climate health concerns.

Research reveals that adults who were hospitalized with RSV experience significant long-term health issues, impacting quality of life and physical function.

Discover the latest FDA-approved treatments, including lumateperone for depression and elinzanetant for menopause symptoms, plus innovative health supplements.

Effective SCD pain management requires an integrated, multimodal strategy across outpatient and inpatient settings.

New research explores the gut-brain connection, suggesting that improving gut health may enhance mental well-being.

Pimavanserin offers a serotonin-targeted option for Parkinson disease psychosis that improves hallucinations and delusions with minimal impact on motor symptoms.

A promising multistage malaria vaccine shows potential for broader protection against the disease, highlighting the evolving role of pharmacists in vaccination efforts.

High levels of C-reactive protein in the blood and lower heart rate variability were linked to cardiovascular events in patients with depression, anxiety, or both.

Lowering blood glucose levels significantly reduces heart disease risks in prediabetes, offering new hope for prevention and management strategies.

The FDA's 2025 biosimilar approvals enhanced treatment options for chronic diseases, improving accessibility and affordability for patients and health care providers.

Continuous glucose monitoring (CGM) significantly reduces the risk of high birth weight in babies born to mothers with gestational diabetes.

Medication errors are major public health issues, disproportionately affecting populations such as children, Ooder adults, and those with limited health literacy.

FDA approves lumateperone as a new adjunct therapy for major depressive disorder, offering hope for those with persistent symptoms despite treatment.

Six months following pneumococcal vaccination, over 70% of patients lost their protective titers, suggesting the need for more optimal vaccination strategies.

Nufymco, the FDA-approved ranibizumab biosimilar, enhances treatment options for retinal diseases, improving patient access and affordability.

Discover how AI-engineered nasal antiviral platforms revolutionize flu prevention, enhancing mucosal immunity and offering new treatment possibilities.

Sarah J. Billups, PharmD, highlights the disconnect between medication adherence metrics and actual patient outcomes, urging a reevaluation of adherence measures in health care.